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Abstract
Background: Supplemental vitamin D modulates inflammatory cytokines and skeletal muscle function, but results
are inconsistent. It is unknown if these inconsistencies are dependent on the supplemental dose of vitamin D.
Therefore, the purpose of this study was to identify the influence of different doses of supplemental vitamin D on
inflammatory cytokines and muscular strength in young adults.
Methods: Men (n = 15) and women (n = 15) received a daily placebo or vitamin D supplement (200 or 4000 IU)
for 28-d during the winter. Serum 25-hydroxyvitamin D (25(OH)D), cytokine concentrations and muscular (leg)
strength measurements were performed prior to and during supplementation. Statistical significance of data were
assessed with a two-way (time, treatment) analysis of variance (ANOVA) with repeated measures, followed by a
Tukey’s Honestly Significant Difference to test multiple pairwise comparisons.
Results: Upon enrollment, 63% of the subjects were vitamin D sufficient (serum 25(OH)D ≥ 30 ng/ml). Serum
25(OH)D and interleukin (IL)-5 decreased (P < 0.05) across time in the placebo group. Supplemental vitamin D at
200 IU maintained serum 25(OH)D concentrations and increased IL-5 (P < 0.05). Supplemental vitamin D at 4000 IU
increased (P < 0.05) serum 25(OH)D without altering IL-5 concentrations. Although serum 25(OH)D concentrations
correlated (P < 0.05) with muscle strength, muscle strength was not changed by supplemental vitamin D.
Conclusion: In young adults who were vitamin D sufficient prior to supplementation, we conclude that a low-daily
dose of supplemental vitamin D prevents serum 25(OH)D and IL-5 concentration decreases, and that muscular
strength does not parallel the 25(OH)D increase induced by a high-daily dose of supplemental vitamin D.
Considering that IL-5 protects against viruses and bacterial infections, these findings could have a broad
physiological importance regarding the ability of vitamin D sufficiency to mediate the immune systems protection
against infection.
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Vitamin D status is influenced by a variety of factors,
including but not limited to geographical latitude, season
and supplement use. Living in extreme northern and
southern climates and the winter season result in low vita-
min D levels [1,2], while supplemental vitamin D increases
serum 25-hydroxyvitamin D (25(OH)D) in a dose-
dependent fashion [3-5]. Serum 25(OH)D is the best indi-
cator of vitamin D status [6], but 1a,25-dihydroxyvitamin
D3 (1,25(OH)D) is the active form of vitamin D that regu-
lates biological functions. In kidney and immune cells,
1a-hydroxylase (1a-OHase) converts 25(OH)D to 1,25
(OH)D. This enzymatic conversion is limited by substrate
availability since 1a-OHase operates below its Km. Thus,
an adequate circulating 25(OH)D concentration is neces-
sary to maintain substrate availability for the enzymatic
conversion of vitamin D to its active form.
Low serum 25(OH)D concentrations result in skeletal
muscle weakness [7,8], and in pathophysiological and phy-
siological conditions, correlate with muscular strength or
physical performance [9-14]. These findings suggest that
increasing serum 25(OH)D concentration improves mus-
cular strength. Consistent with this deductive reasoning,
supplemental vitamin D reversed vitamin D deficiency-
induced weakness in elderly [10,15] and in patients with
diverse diseases or illnesses [16-18]. Although we pre-
viously demonstrated that serum 25(OH)D concentration
is influential on muscle strength recovery following liga-
mentous injury and surgery in active adults [19], it is
unknown if supplemental vitamin D increases muscular
strength simultaneous with serum 25(OH)D concentra-
tions in young, reportedly active and healthy adults.
Vitamin D regulates inflammatory cytokines, which
orchestrate host defenses by the immune system. Inter-
feron (IFN)-g is a cytokine that regulates T helper 1 (TH1)-
type cells and pathways [20-22], and in immune cells, is
regulated by vitamin D [23-25]. Interleukin (IL)-5 and IL-
10 regulate TH2-type cell pathways [26-30] and are modu-
lated by vitamin D [31-34]. Despite previous reports iden-
tifying the influence of vitamin D on cytokine production
in vitro, evidence illustrating concurrent alterations in
serum 25(OH)D and cytokine concentrations in humans
is more ambiguous. For example, in healthy-adults during
the winter, low serum 25(OH)D concentrations corre-
sponded with increased IFN-g and IL-10 production [35],
while supplemental vitamin D (cholecalciferol) increased
IL-10 in congestive heart failure patients [36] but was inef-
fective at modulating IFN-g, IL-5 or IL-10 in overweight
or obese subjects [37]. Currently, it is unknown if supple-
mental vitamin D modulates inflammatory cytokines con-
comitantly with serum 25(OH)D concentrations in young,
healthy adults during the winter.
To date, one study has examined the influence of dif-
ferent doses of supplemental vitamin D on serum 25
(OH)D simultaneously with circulating cytokines in
healthy adults during the winter, and the range of sup-
plemental vitamin D (cholecalciferol) doses were narrow
(i.e., 200, 400 and 600 IU/d) [38]. Additionally, it is
unknown whether short-term and different doses of
supplemental vitamin D modulate muscular strength
similarly despite divergent serum 25(OH)D concentra-
tion responses. Therefore, the purpose of this study was
to identify the influence of low and high doses of sup-
plemental vitamin D on serum 25(OH)D, inflammatory
cytokines and muscular strength in young adults during
the winter. We hypothesized that a ‘low’ daily dose of
supplemental vitamin D maintains serum 25(OH)D con-
centration, and that a ‘high’ daily dose is necessary to
modulate circulating cytokines and muscular strength in
young adults during the winter. To test this hypothesis,
subjects were provided a daily placebo supplement or
supplemental vitamin D at different doses (200 or 4000
IU) in a randomized, double-blind experimental design.
Supplements were taken for 28-d during the winter, and
serum 25(OH)D, cytokine and muscular strength mea-
surements were performed prior to and during the sup-
plemental intervention in young, reportedly active and
healthy adults. We demonstrate in young adults who
were vitamin D sufficient prior to supplementation that
a low-daily dose of supplemental vitamin D prevents
serum 25(OH)D and IL-5 concentration decreases, and
that muscular strength does not parallel the 25(OH)D
increase induced by a high-daily dose of supplemental
vitamin D.
Methods
The Institutional Review Board at Intermountain Health-
care (Murray, UT, USA) approved this study. Subjects
were informed of the experimental protocol and proce-
dures and provided both written and verbal consent prior
to participation. Recreationally active (minimum of 30
minutes of continuous exercise at least 3 time per week
for 1 year prior to enrollment), non-smoking males and
females between the ages of 18 and 45 years of age were
recruited to participate in this study. Subjects were
excluded from participation if they experienced a lower-
extremity injury or injuries during the year prior to
enrollment. Subjects were also excluded from participa-
tion if they were taking a daily dietary-supplement during
the previous year, planning on increasing or decreasing
the amount of time spent in the sun or tanning bed, or
traveling south of 37°N latitude during enrollment. Sub-
jects were asked to refrain from using any other supple-
ments during study participation. Data was collected
during two successive winters. First, between December
1, 2009 and April 26, 2010, and second, between Decem-
ber 1, 2010 and March 15, 2011 in Salt Lake City, UT
USA (40°N latitude). We chose to collect data during the
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nadir. This occurs because the solar angle during the
winter is inadequate to stimulate cutaneous vitamin D
synthesis from sun (ultraviolet B radiation) exposure.
Study design and protocol
This study consisted of a randomized, double-blind, pla-
cebo-controlled experimental design. Subjects were ran-
domly assigned to one of three groups: vitamin D
(cholecalciferol) supplementation at: (1) 200 or (2) 4000
IU, or (3) a matching-placebo. Supplements were taken
daily for 28-d. Supplements were permutated into ran-
dom blocks of six. Subjects were asked to refrain from
using aspirin, ibuprofen, naproxen sodium, and acetami-
nophen throughout the duration of the study.
It should be noted, that upon study initiation, 200 IU/d
of vitamin D was the recommended-adequate intake and
4000 IU/d was double the upper limit for the targeted
population. Currently, 200 IU/d is lower than the current
recommended dietary allowance and 4000 IU is the upper
limit for the studied population. These recommendations
a r ep r o v i d e db yt h eI n s t i t u t eo fM e d i c i n ef o rt h eU n i t e d
States and Canada [39]. Although recommendations chan-
ged during the course of this study, the experimental
design (randomized, double-blind, placebo-controlled) and
the examination of two different doses of supplemental
vitamin D are strengths of this investigation.
Analytical procedures
Each subject provided five fasting blood draws: (1) prior to
(Pre), and (2) 7-, (3) 14-, (4) 21- and (5) 28-d after supple-
mentation. Subjects were asked to refrain from physical
activity 72-h prior to each blood draw to ensure that prior
activity did not confound serum 25(OH)D and cytokine
concentration results. Fasting blood draw samples were
obtained from the antecubital vein into one 4.0 ml purple-
top Becton Dickinson (BD) Vacuatainer tube (K2 EDTA
7.2 mg), one 4.5 ml light green-top BD Vacutainer tube
(PST Gel and Lithium Heparin, 83 units), and one 6.0 ml
red-top serum BD Vacutainer tube. Plasma was separated
by centrifugation (Heraeus Labofuge 400 series, Buckin-
ghamshire, England) at 2400 g for 6 min within 20 min of
sample collection. Following separation, plasma samples
were sent to clinical laboratories for analytical chemistries
(see below). Serum was separated by centrifugation (VWR
International, Clinical 50 Centrifuge) at 1100 g for 20 min
within 20 min of sample collection and after coagulation.
Serum samples were immediately stored at -80°C (Revco
Freezer, GC Laboratory Equipment, Asheville, NC, USA)
until the day of 25(OH)D and cytokine concentration ana-
lyses (see below).
Serum 25(OH)D concentrations
Serum 25(OH)D concentrations (ng/ml) were measured
at USANA Health Sciences, Inc. (Salt Lake City, UT
USA) using a modified Bligh-Dyer technique for extrac-
tion [40] and a scaled-down and modified method as pre-
viously described [41]. Briefly, 100 μl of serum was added
to 400 μL of a 2:1 methanol:chloroform solution contain-
ing dueterated 25(OH)D3 as an internal standard (10 ng/
mL in the stock solution; 40 ng/mL final concentration)
in a 2 mL centrifuge tube. Samples were immediately
vortexed and allowed to sit on ice for 10 min. Samples
were then spun at 15,000 g for 5 min and the supernatant
transferred to a new 2 mL centrifuge tube containing 500
μL chloroform. Samples were vortexed and allowed to
stand for 5 min. To achieve phase separation, 750 μLo f
ddH2O was added, vortexed, and centrifuged for 2 min at
15,000 g. The aqueous phase (top), and any debris
between the two phases, was removed and discarded.
The remaining organic phase was dried down to comple-
teness in a centrifugal vacuum concentrator for 18 min
at 45°C under negative pressure. The pellet was then
resuspended in 100 μL of methanol and added to high
performance-liquid chromatography (HPLC) vials.
Analytes were separated by injecting 10 μL into an Agi-
lent HPLC (series 6410, Model G6410B, Santa Clara, CA
USA) and a Phenomenex Inertsil 3 micron, 150 × 4.60
mm column. Method conditions were: 0-8 min, 90%
MeOH/10% (0.03% formic acid in water); 8-15 min, 30%
MeOH/70% 2-propanol; 15-20 min, 90% MeOH/10%
(0.03% formic acid in water). 25(OH)D2 and 25(OH)D3
were detected on an Agilent tandem mass spectrometer
(Series 6410, Model G6410B, Sant clara CA USA) using
atmospheric pressure chemical ionization (APCI) detec-
tion (350°C gas temperature, 400°C vaporizer). The
25(OH)D3, dueterated 25(OH)D3 and 25(OH)D2 precur-
sor ions were 383.3, 386.3 and 395.4, respectively. The
25(OH)D3, dueterated 25(OH)D3 and 25(OH)D2 produc-
tions were 365.3, 368.3 and 208.9, respectively. Serum 25
(OH)D2 and 25(OH)D3 concentrations were determined
relative to authentic standards and corrected for recovery
of the 25(OH)D3 internal standard. The detection limit
was determined to be < 1 ng/ml for all analytes. The sum
of 25(OH)D2 and 25(OH)D3 concentrations was used as
the 25(OH)D total concentration. However, since serum
25(OH)D2 was not detected in any subjects, serum 25
(OH)D total concentrations are referred to as serum 25
(OH)D concentrations hereafter.
Cytokines
A multiplex microsphere-bead array was used to mea-
sure a number of circulating inflammatory cytokines
(pg/ml) as described previously [42,43]. Briefly, IFN-g,
IL-5 and IL-10 were quantitated using a multiplexed
sandwich capture assay developed in the ARUP Institute
for Clinical and Experimental Pathology (University of
Utah, Salt Lake City, UT, USA) using the Luminex
Multi-Analyte Profiling system (Luminex, Austin, TX,
USA) [42].
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tiplex-cytokine bead assay previously [42,43]. In brief,
using independent control samples of low, medium, and
high concentrations the coefficient of variation was cal-
culated on 5 replicates. The intra-assay coefficient of var-
iation was predominantly less than 10%. The inter-assay
coefficient of variation was predominantly less than 15%
for the medium and high control samples and up to
~30% for the low control sample [42,43].
Clinical chemistries
Plasma parathyroid hormone (PTH; pg/ml) and calcium
(mg/dl) concentration measures were performed at
ARUP Laboratories (Salt Lake City, UT USA). Plasma
creatinine (mg/dl) concentrations were measured at the
Central Laboratory with Intermountain Healthcare (Mur-
ray, UT USA).
To assess renal function prior to and following supple-
mentation, the estimated glomerular filtration rate (eGFR;
ml/min/1.73 m
2) was calculated by the following equation:
eGFR = 186×

creatinine/88.4
−1.154×

age
−0.203×(0.742 if female)×(1.210 if black)
Single-leg strength testing
Subjects with strength or power output asymmetry (i.e., >
5% difference in peak isometric or power output between
l e g s )w e r ee x c l u d e df r o mp a r t i c i p a t i o n .L e gs t r e n g t h
from a single randomly selected leg was performed prior
to (Pre) and 28-d after (Post) placebo or vitamin D sup-
plementation. Single-leg strength testing was performed
on a horizontal plyo-press (Athletic Republic, Park City,
UT USA). Plyo-press output data were measured from
output signals obtained from a mounted force plate
(Advanced mechanical Technology, Watertown, MA
USA) and displacement transducer (UniMeasure PA-50-
NJC, Corvallis, OR USA). All data were sampled at 200
Hz with a low-pass filter at 10 Hz using DartPower soft-
ware (Athletic Republic, Park City, UT USA, version 2.0).
Before every testing session, the mounted force plate was
zeroed and load calibrated.
For the single-leg peak isometric force measurements,
the plyo-press sled was adjusted for each subject to align
the knee and hip joint flexion angles to 90° with the
abdominal, lower back region secured and stabilized to
the plyo-press sled with a harness. The plyo-press sled
position was documented and reproduced to achieve the
desired knee and hip joint flexion angles at the follow-up
visits. Leg selection was randomized. Subjects were verb-
ally instructed and strongly encouraged to exert maximal
force against the mounted force platform. Each subject
performed three maximal single-leg isometric contrac-
tions. Each isometric contraction was 3 sec in duration
and separated by approximately 1 min. Peak isometric
force (N/kg) was defined as the highest resultant force
applied during the 3 sec test for each trial. To calculate
average isometric force, peak isometric forces from the 3
trials at each visit were averaged.
Single-leg peak power output measures followed the
single-leg isometric contractions and were measured on
the same horizontal plyo-press with the same securing
procedures described above. Starting from an extended
position (full extension = 0°), subjects performed repeti-
tive single-leg jumps (i.e., hip and knee flexion-extension
cycles) as fast as possible. Subjects were instructed to
jump as high as possible. Each test was 20 sec in dura-
tion with the weight-stack resistance set at 75% of body
mass. The time-aligned product of the resultant forces
( N )a c q u i r e df r o mt h ef o r c ep l a t f o r ma n dw e i g h t - s t a c k
velocities (m/s) data obtained from the displacement
transducer were used to calculate power output and
expressed relative to body mass (W/kg). Peak power
output was defined as the highest power output pro-
duced during the 20 sec test for each leg. The peak
power output for each jump during the 20 sec test were
averaged to provide an average power output for each
testing session in each leg.
Statistical analyses
To achieve normality, rank transformations were per-
formed on eGFR, serum 25(OH)D changes from Pre, and
serum cytokine changes from Pre. Transformations were
checked for normality with a Kolmogorov-Smirnov test.
Statistical significance of data were assessed with a two-
way (time, treatment) analysis of variance (ANOVA) with
repeated measures, followed by a Tukey’sH o n e s t l yS i g -
nificant Difference to test multiple pairwise comparisons.
One-way ANOVA tests were performed on subject char-
acteristics. Relationships between variables were exam-
ined with a Pearson Product Moment Correlation. All
statistical analyses were performed with SysStat software
(SigmaPlot 10.0, SigmaStat 3.5, Chicago, IL, USA). Statis-
tical significance was set at a P < 0.05. Data presented as
mean (SD) unless otherwise noted.
Results
Subject characteristics
Subject characteristics were similar between groups
(Table 1). For example, there was less than a 6% differ-
ence in body mass, and importantly, less than a 1% differ-
ence in BMI between vitamin D groups (i.e., 200 vs. 4000
I U ;T a b l e1 ) .T h i si sas t r e n g t ho ft h ep r e s e n ts t u d y
because it identifies similar body sizes between supple-
mental vitamin D groups.
Baseline vitamin D status
Upon enrollment, serum 25(OH)D concentrations were
32.2 (10.0) ng/ml. Prior to randomization, 13.3 (n =4 ) ,
23.3 (n = 7) and 63.3% (n = 19) of the subjects were vita-
min D deficient (serum 25(OH)D ≤ 20 ng/ml), insufficient
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(OH)D ≥ 30 ng/ml), respectively.
Following randomization, 30, 20 and 50% of the sub-
jects in the placebo group started study participation
vitamin D deficient, insufficient or sufficient, respec-
tively. In the 200 IU group, 10% were deficient, 20%
were insufficient and 70% were sufficient, and in the
4000 IU group, 30% were insufficient and 70% were suf-
ficient when starting study participation. Based on these
data, starting vitamin D status was sufficient at the
group level and in groups assigned to different supple-
mental treatments.
Serum 25(OH)D concentrations
Treatment efficacy was evaluated by measuring serum 25
(OH)D concentrations. Serum 25(OH)D concentrations
progressively and significantly (P < 0.05) increased in 4000
I Ug r o u pa n dc o m p a r e dt ot h o s ei nt h ep l a c e b oa n d2 0 0
IU groups (Figure 1). Surprisingly, supplemental vitamin
Da t2 0 0I Ui n c r e a s e ds e r u m2 5 ( O H ) Dc o n c e n t r a t i o n s
compared to those in the placebo group (Figure 1).
Since vitamin D status tended (albeit non-significantly)
to be higher in the 200 IU group upon study enrollment
(Figure 1), serum 25(OH)D was normalized to Pre concen-
trations (change from Pre). Serum 25(OH)D concentration
changes were not significantly different in the placebo or
200 IU groups (Figure 2). In contrast, serum 25(OH)D
concentration changes significantly (P < 0.05) increased in
the 4000 IU group and compared to those in placebo and
200 IU groups (Figure 2). At 21-d and 28-d, serum 25(OH)
D concentration changes were significantly (P < 0.05) dif-
ferent between the placebo and 200 IU groups (Figure 2).
Altogether, these data indicate that 200 IU of supple-
mental vitamin D protected against a seasonal decrease
while 4000 IU induced a rapid increase in serum 25
(OH)D concentrations.
Clinical chemistries
Due the anticipated seasonal decrease (which could
change vitamin D status from sufficient to insufficient)
and the efficacy of supplemental vitamin D at 4000 IU
to increase serum 25(OH)D concentrations, PTH and
calcium were measured in each blood draw sample.
PTH and calcium concentrations were not significantly
different within or between groups (Table 2). Along
with creatinine measures, the eGFR was calculated to
Table 1 Subject characteristics
Placebo 200 IU 4000 IU
n (males/females) 10 (5/5) 10 (4/6) 10 (6/4)
Age (y) 30.2 (4.8) 26.6 (3.2) 29.0 (5.0)
Height (cm) 167 (14) 169 (9) 173 (9)
Body mass (kg) 72.5 (17.2) 69.4 (17.2) 73.3 (15.3)
Body mass index (kg/m
2) 25.5 (3.0) 24.0 (4.1) 24.2 (3.6)
Data presented as mean (SD) unless otherwise noted
Twenty-nine subjects were Caucasian; one subject was African American
(placebo group)
Figure 1 Serum 25(OH)D concentrations (ng/ml) were
significantly (P < 0.001, treatment, time interaction) modified
following supplementation. Although there were no significant
differences in the placebo or 200 IU groups, serum 25(OH)D
concentrations increased after 7-d (
1 P < 0.001 vs. Pre) and continued
to increase thereafter (
2P < 0.001 vs. Pre and 7-d;
3P < 0.001 vs. Pre,
7-d, 14-d and 21-d) in the 4000 IU group. Serum 25(OH)D
concentration differences between groups at Pre were not
significant. However, serum 25(OH)D concentrations were
significantly (*P < 0.05 vs. placebo) increased in the 200 and 4000 IU
groups compared to those in the placebo group after
supplementation. By 28-d, serum 25(OH)D concentrations were
significantly (
#P < 0.05 vs. 200 IU) increased in the 4000 IU compared
to those in the 200 IU group. Data presented as mean (SD).
Figure 2 Serum 25(OH)D concentration (ng/ml) changes from
Pre were significantly (P < 0.005, treatment, time interaction)
modulated following supplemental vitamin D. Serum 25(OH)D
changes from Pre were significant (
1P < 0.05 vs. 7-d) in the 4000 IU
group and compared to the corresponding placebo (*P < 0.05 vs.
placebo) and 200 IU (
#P < 0.05 vs. 200 IU) changes. Serum 25(OH)D
concentration changes were also significantly (*P < 0.05 vs. placebo)
different between the placebo and 200 IU groups at 21-d and 28-d.
Data presented as mean (SD).
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significantly different within or between groups (Table 2).
Thus, the seasonal decrease and supplemental vitamin D-
mediated increase in serum 25(OH)D concentrations did
not manifest in PTH, calcium, creatinine or eGFR
alterations.
Inflammatory cytokines
Cytokine data was normalized to Pre concentrations
because of variability. Following supplementation, IFN-g
(Figure 3A) and IL-10 (Figure 3B) were not significantly
different. In contrast, there was a transient and significant
(P < 0.05) IL-5 decrease in the placebo group (Figure 3C).
Furthermore, IL-5 significantly (P < 0.05) increased in the
200 IU group and compared to that in the placebo group
at 28-d (Figure 3C). Vitamin D supplementation at 4000
IU/d did not significantly change serum IL-5 concentra-
tions (Figure 3C). When taken in the context that our
cytokine data was variable and collected in healthy adults
who were monitored for only 28-d during the winter
without exposure to any undue distress, these robust and
unique findings illustrate that supplemental vitamin D
maintains serum 25(OH)D and IL-5 concentrations.
Single-leg isometric forces and power outputs
Vitamin D modulates muscular strength and power out-
put. Herein, after 28-d of supplemental vitamin D at
200 or 4000 IU/d, and compared to those in the placebo
group as well, peak (Figure 4A) or average (Figure 4B)
Table 2 Plasma clinical chemistries
placebo 200 IU 4000 IU
PTH (pg/ml)
Pre 36.1 (13.9) 36.1 (14.6) 31.4 (10.3)
7-d 40.7 (16.5) 35.8 (16.4) 30.8 (11.4)
14-d 38.5 (11.0) 31.7 (13.1) 30.3 (7.9)
21-d 35.0 (13.5) 31.1 (11.0) 25.9 (8.3)
28-d 35.5 (12.6) 33.0 (17.9) 32.1 (11.4)
calcium (mg/dl)
Pre 9.22 (0.27) 9.36 (0.26) 9.32 (0.22)
7-d 9.06 (0.16) 9.21 (0.38) 9.38 (0.26)
14-d 9.15 (0.24) 9.22 (0.27) 9.41 (0.21)
21-d 9.09 (0.31) 9.38 (0.29) 9.30 (0.28)
28-d 9.16 (0.24) 9.39 (0.35) 9.35 (0.23)
creatinine (mg/dl)
Pre 0.93 (0.08) 0.91 (0.14) 0.98 (0.17)
7-d 0.92 (0.08) 0.97 (0.16) 0.98 (0.15)
14-d 0.94 (0.09) 0.92 (0.13) 0.97 (0.17)
21-d 0.92 (0.13) 0.92 (0.15) 0.98 (0.15)
28-d 0.94 (0.16) 0.91 (0.15) 1.01 (0.13)
eGFR (ml/min/1.73 m
2)
Pre 90.9 (15.6) 91.9 (12.6) 87.7 (11.3)
7-d 91.1 (12.3) 85.5 (15.0) 87.5 (10.2)
14-d 89.1 (13.0) 89.7 (9.2) 89.5 (12.5)
21-d 91.6 (8.0) 91.0 (13.2) 88.0 (12.5)
28-d 90.2 (12.1) 92.1 (14.3) 84.7 (9.3)
Data presented as mean (SD)
Figure 3 Serum IFN-g, IL-10 and IL-5 concentration (pg/ml)
changes from Pre. Serum IFN-g (A) and IL-10 (B) concentration
changes were not significantly different within or between groups.
However, IL-5 (C) displayed a significant (P < 0.05) treatment, time
interaction. Although no significant differences were observed
within the 4000 IU group, there was a significant and transient
decrease in IL-5 at 14-d (
1P < 0.05 vs. 7-d) in the placebo and
increase at 28-d (
2P < 0.05 vs. 7-d and 14-d) in 200 IU group. At 28-
d, IL-5 changes were also significantly (*P < 0.05) different between
the placebo and 200 IU groups. Figure legend provided in ‘A’. Data
presented as mean (SD).
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wise, peak (Figure 5A) and average (Figure 5B) power
outputs were not significantly different between supple-
mental groups. However, there was a significant main
effect of time on peak (P < 0.05; Figure 5A) and average
(P < 0.05; Figure 5B) power outputs, thereby indicating
a learning effect.
Correlations
Although supplemental vitamin D did not significantly
change isometric forces, peak (r =0 . 2 7 ,P <0 . 0 5 )a n d
average (r = 0.29, P < 0.05) isometric forces correlated
with serum 25(OH)D concentrations.
Discussion
Vitamin D regulates inflammatory cytokines and skeletal
muscle function, especially in isolated immune cells and
various pathophysiological conditions in humans. In the
present investigation, we extend those previous reports
by providing several original and impactful results
obtained from healthy adults during the winter. First, we
provide new data identifying serum 25(OH)D and IL-5
concentration decreases. Secondly, supplemental vitamin
D at 200 IU/d prevented serum 25(OH)D and IL-5 con-
centration decreases. Third, supplemental vitamin D at
4000 IU/d induced an immediate increase in serum 25
(OH)D concentrations without modulating circulating
IL-5. Finally, despite serum 25(OH)D concentrations
correlating with muscle strength, supplemental vitamin
D did not moderate muscular strength alterations.
T h e s eu n i q u ed a t ai n d i c a t et h a ts u b t l ef l u c t u a t i o n si n
serum 25(OH)D concentrations modulate a TH2-type
cytokine, and that muscular strength does not parallel
the rapid serum 25(OH)D increase induced by a high-
daily dose of supplemental vitamin D in young, report-
edly active and healthy adults.
As expected, serum 25 (OH) D concentrations
responded disparately to different doses of supplemental
vitamin D (Figures 1 and 2). Compared to serum 25(OH)
D concentrations prior to supplementation, we observed a
15% increase after 7-d, which progressively inflated by
~50% after 28-d of supplemental vitamin D at 4000 IU/d.
Thus, in subjects with mean serum 25(OH)D concentra-
tions in the low-30 ng/ml range prior to supplementation,
4000 IU/d of supplemental vitamin D induced a rapid and
continuous increase in serum 25(OH)D concentrations
Figure 4 Single-leg isometric forces (N/kg).S i n g l e - l e gp e a k( A)a n da v e r a g e( B) isometric forces were not significantly different within or
between groups. Figure legend provided in ‘A’. Data presented as mean (SD).
Figure 5 Single-leg power outputs (W/kg).S i n g l e - l e gp e a k( A) and average (B) displayed significant (both P < 0.05) main effects of time.
Specifically, peak (A) and average (B) power outputs were significantly (
1P < 0.05) greater at 28-d vs. Pre. Data presented as mean (SD).
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Page 7 of 12during the winter for 28-d. Conversely, in the 200 IU
group, serum 25(OH)D concentrations did not change,
while serum 25(OH)D concentrations decreased in the
placebo group (Figure 2; 21-d and 28-d). These are impor-
tant findings because they establish consistency with pre-
vious studies that identify a decrease in serum 25(OH)D
concentrations during the winter [1,38]. Moreover, our
results indicate that at our geographical location, 200 IU/d
of supplemental vitamin D plus daily dietary intake of vita-
min D is adequate to maintain serum 25(OH)D concentra-
tions and vitamin D sufficiency during the winter, at least
in adult non-smokers and during 28-d. However, our data
obtained at 200 IU/d of supplemental vitamin D dispute
previous findings. Specifically, Barnes et al. [38] recently
demonstrated that 200 IU of daily vitamin D supplementa-
tion was ineffective at maintaining serum 25(OH)D con-
centrations during winter [38]. The more Northern
geographical latitudes (51° and 55°N) and plausibly the
longer supplementation duration (22 weeks) in the study
by Barnes et al. [38] could be contributing factors for the
discrepancy in maintaining serum 25(OH)D concentration
between studies that were conducted at the same reported
supplemental dose of vitamin D. This interpretation
would further suggest the dose of supplemental vitamin D
(plus dietary intake) required to maintain a given serum
25(OH)D concentration increases with increasing North-
ern latitudes during the winter. Another explanation for
the discrepancy between Barnes et al. [38] and those
herein could be differences in dietary vitamin D intake.
Unfortunately, neither Barnes et al. [38] nor do we report
vitamin D intake from dietary sources. Future studies are
encouraged include dietary sources (and sun exposure) of
vitamin D when investigating serum 25(OH)D concentra-
tions at daily doses of supplemental vitamin D that are
easily achievable through dietary sources. Finally, it is
probable that subjects randomized to the 200 IU group
had a lower percentage of body fat compared to those by
Barnes et al. [38]. This could potentially lower the physio-
logical needs of vitamin D in the 200 IU group due to less
sequestering to adipose tissue. We speculate that the good
vitamin D status reflected by our subjects prior to supple-
mentation is indicative of sun exposure during the preced-
ing summer and fall and daily dietary habits that include
vitamin D, such as the consumption of oily fish and vita-
min D fortified food sources.
A novelty of the present investigation was the IL-5
results obtained with and without supplemental vitamin
D (Figure 3C). In the placebo group, there was a transient
IL-5 decrease, while in contrast, IL-5 increased in the 200
IU and remained unchanged in the 4000 IU group. Due
to the small sample and effect sizes, it is plausible that
200 IU of supplemental vitamin D maintained as opposed
to increased IL-5. This premise is logically harmonious
with the data obtained in the 4000 IU group, which in
sum suggests that supplemental vitamin D maintains
serum 25(OH)D and IL-5 concentrations during the win-
ter. However, consistent with our increase in the 200 IU
group, Qi et al. [44] demonstrated that vitamin D (i.e.,
1,25(OH)D) pre-treatment in rats injected-intraperitone-
ally with lipopolysaccharide (LPS) increased IL-5 gene
expression in the spleen [44]. Similarly, IL-5 production
increased in CD4
+ cells obtained from mice when incu-
bated in 1,25(OH)D and stimulated with IL-2, phorbol
myristate acetate (PMA) and ionomycin [45]. These
results indicate that the active metabolite form of vitamin
D increases IL-5. However, results vary. In an experimen-
tal mice model of pulmonary eosinophilic inflammation,
subcutaneous 1,25(OH)D injections abrogated IL-5 pro-
duction in bronchoalveolar lavage fluid [46]. Further-
more, when stimulated with PMA and ionomycin in the
presence of 1,25(OH)D, IL-5 production decreased in
TH0-cells and remained unchanged in TH1- and TH2-cells
[47]. Regarding no change in IL-5, Yusupov et al. [48]
demonstrated that vitamin D (cholecalciferol) supple-
mentation at 2000 IU/d for 3 months was ineffective at
altering circulating IL-5 concentrations in young, healthy
adults. Thus, these latter studies potentially conflict with
our results at 200 IU but are in agreement with those
reported herein at 4000 IU. Collectively, these findings
highlight that the cytokine-modulating property of vita-
min D could be physiologically dependent on the supple-
mental dose (and/or environmental factors and dietary
intake), the immunological challenge (or lack thereof),
experimental model (i.e., humans, rodents, or cell), dura-
tion of vitamin D treatment, the timing of data collection,
and importantly, the form of vitamin D studied.
Regarding the form of vitamin D, most studies have
investigated the influence of 1,25(OH)D on inflammatory
cytokines in vitro, which makes it is difficult to equate or
interpret results relative to supplemental D or serum
25(OH)D concentration studies in humans that do not
report 1,25(OH)D. Recently, Zhang et al. [49] demon-
strated that 15 ng/ml of serum 25(OH)D was ineffective at
suppressing LPS-induced cytokine (i.e., IL-6 and TNF-a)
production in human monocytes studied in vitro.I nc o n -
trast, 30 ng/ml of serum 25(OH)D significantly inhibited
cytokine production and was comparable to that shown at
0.04 ng/ml of 1,25(OH)D [49]. These paramount findings
indicate that serum 25(OH)D concentration, and impor-
t a n t l yas p e c i f i cc i r c u l a t i ng concentration (i.e., ≥ 30 ng/
ml), is of physiological relevance regarding the anti-inflam-
matory property of vitamin D because its availability in the
circulation influences the local tissue production of
1,25(OH)D [49].
Vitamin D receptors are located on T-cells and mast
cells [50,51], and along with eosinophils, are sources of
IL-5 [52]. IL-5 is essential for promoting eosinophil
growth, differentiation, survival and activation, and is
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IL-4 and IL-13 [53,54]. GATA-3 is a transcription factor
that promotes IL-5 gene expression and promoter-trans-
activation in TH2-cells [48,55]. In CD4
+ cells derived
from mice, GATA-3 message expression increased when
incubated with 1,25(OH)D [56]. In an experimental
mouse model of allergic induced-asthma, 1,25(OH)D
up-regulated the message expression of GATA-3 [57].
Thus, we speculate that maintaining serum 25(OH)D
concentrations is necessary to sustain substrate availabil-
ity for the conversion to 1,25(OH)D, which subsequently
modulates GATA-3 expression and prevents IL-5
decreases. With that said, it is unclear why IL-5 did not
increase in the 4000 IU group, unless there was a transi-
ent increase (or decrease) that was not detected with the
timing of our blood sampling procedures.
Evidence indicates that several types of hyper-eosinophi-
lic syndromes are mediated by IL-5 [58]. In patients with
hyper-eosinophic syndrome, an anti-IL-5 monoclonal anti-
body (i.e., mepolizumab) spared corticosteroid use [59],
which is of clinical importance since long-term corticos-
teroid use is associated with adverse events. Anti-IL-5
treatment also reduced the disposition of extracellular
matrix proteins in bronchial biopsies obtained from atopic
asthmatic patients [60], suggesting that neutralizing IL-5
minimizes the repair process following airway injury and
eosinophilia. However, the increase in IL-5 could be bene-
ficial. In addition to increasing eosinophils, IL-5 enhances
immunoglobulin A (IgA) production [61,62], which pro-
tects against a variety of viruses and bacterial infections
[for review see [55]]. Recently, Halliday et al. [63] found
that serum 25(OH)D concentrations inversely correlated
with frequency of illness in collegiate athletes. Perhaps,
maintaining or increasing IL-5, as observed in our supple-
mental vitamin D groups (Figure 3C) who also maintained
or increased as opposed to decreased serum 25(OH)D
concentrations (Figure 2), could be beneficial by inducing
IgA and the resistance against infectious challenge, such as
the influenza virus [64]. Clearly, this premise warrants
additional research.
In contrast to our hypothesis, supplemental vitamin D
did not increase muscular strength (Figure 4A and 4B) or
power (Figure 5A and 5B) despite serum 25(OH)D
concentrations increasing by ~50% in the 4000 IU group
(Figure 1). This finding extends previous reports [65-67]
suggesting that supplemental vitamin D does not improve
muscular strength. However, previous reports, and includ-
ing the results here, are not consistent with the majority of
the data. There could be several reasons for the inconsis-
tencies. First, vitamin D insufficiency or deficiency results
in muscular weakness [7,8]. Compromised muscle
strength correlated with serum 25(OH) concentrations in
vitamin D deficient adolescent girls [7,9]. In vitamin D
deficient elderly and stroke and osteomalacia patients,
supplemental vitamin D improved muscle strength con-
currently with serum 25(OH)D concentrations [15,16,
18,68]. Furthermore, increasing serum 25(OH)D concen-
trations from ~9 to 16 ng/ml improved muscle strength
and function; further but less pronounced strength and
function improvements occurred from ~16 to 38 ng/ml in
elderly [11], thereby indicating a diminished return in
muscle strength with increasing serum 25(OH)D concen-
trations. In the present investigation, serum 25(OH)D con-
centrations were ≈ 32 ng/ml for all subjects prior to
supplementing (Figure 1), and therefore, subjects were
vitamin D sufficient prior to supplementing. Evidence sup-
porting vitamin D sufficiency is also provided by the PTH
and calcium concentrations (Table 2), which were within
normal clinical reference ranges prior to and following
supplementation and despite 25(OH)D decreases in the
placebo group. Based on the existing literature and the
data presented here, individuals with vitamin D insuffi-
ciency or deficiency could be more prone to muscular
strength improvements with increasing serum 25(OH)D
concentrations than those who are already vitamin D suffi-
cient [68,69]. This theory would explain why muscle
strength did not improve despite an increase in serum 25
(OH)D concentrations following vitamin D supplementa-
tion at 4000 IU/d in subjects who were already vitamin D
sufficient.
Another probable explanation for the inconsistencies in
the literature is that there are few prospective, randomized
studies investigating the influence of supplemental vitamin
D on serum 25(OH)D concentrations and muscular
strength. The majority of the evidence identifying the
beneficial influence of vitamin D on muscular strength or
physical performance is correlative [9,11,12,14,69] or
between groups demarcated on circulating 25(OH)D
concentrations [13,19]. From these data, authors have con-
cluded that increasing circulating 25(OH)D concentrations
improves muscular strength or physical performance.
Finally, our study was conducted in young adults (men
and women). Studies identifying the positive influence of
supplemental vitamin D on muscular-based outcomes
have been conducted in elderly [10,15], in patients with
diverse diseases or illnesses [16-18] or in experimental ani-
mals [70,71]. It is plausible that healthy lifestyles in young
adults mask the influence of supplemental vitamin D on
muscular strength [72]. Although few arguments exist
refuting the influence of vitamin D on muscular strength,
future randomized trials incorporating various vitamin D
dosing regimens that increase serum 25(OH)D concentra-
tions differentially are required to confirm causation in
young adults.
Study limitations include: first, a rather short-interven-
tion phase. Future studies are encouraged to conduct
longer durations of supplemental interventions when
examining the influence of vitamin D on inflammatory
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physical activity was not stringently examined. Record-
ing activities and activity intensities and volumes per-
formed during the preceding seasons both indoor and
outdoor is recommended. Third, this study consisted of
thirty subjects total (n = 10/group). Future studies inves-
tigating the influence of different doses of supplemental
vitamin D on inflammatory cytokines and muscle
s t r e n g t ha r ee n c o u r a g e dt oi n c l u d eal a r g e rs a m p l es i z e .
Fourth, our data collection was limited to weekly blood
draws and emerging evidence is suggesting that the cyto-
kine modulating property of vitamin D could be time
sensitive [34]. Thus, future studies should consider the
temporal cytokine response mediated by vitamin D, espe-
cially at higher doses of supplemental vitamin D that
increase serum 25(OH)D concentrations rapidly. Next,
there was variability across time in the cytokine data. To
account for this variability statistically, we performed a
rank transformation to achieve normality and equal var-
iance. Finally, serum 25(OH)D, inflammatory cytokines
and muscular strength might respond differently in
diverse populations or conditions, such as in obese, smo-
kers, elderly or critically ill. Thus, extrapolating the pre-
sent findings to other populations is not recommended.
In summary, low and high doses of supplemental vita-
min D prevented serum 25(OH)D and IL-5 decreases in
vitamin D sufficient adults during the winter. These
impactful findings defy current belief by suggesting that
a low dose of supplemental vitamin D (plus dietary
i n t a k e )t h a ti se a s i l ya t t a i n a ble through dietary sources
maintains serum 25(OH)D and IL-5 concentrations.
Additionally, despite concentrations correlating with
muscle strength, our shocking data reveal that muscular
strength does not parallel the increase in serum 25(OH)
D concentrations induced by supplemental vitamin D at
4000 IU/d. We conclude that maintaining serum 25(OH)
D concentration during the winter prevents a TH2-type
cytokine decrease, which could be influential in protect-
ing against viral and bacterial infections; and apparently
in reportedly healthy and vitamin D sufficient adults, that
a further increase in serum 25(OH)D mediated by a high
dose of supplemental vitamin D does not improve mus-
cular strength.
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